BR112012005338A2 - anticorpos humanos de afinidade alta para receptor-2 ativado por protease humana. - Google Patents

anticorpos humanos de afinidade alta para receptor-2 ativado por protease humana.

Info

Publication number
BR112012005338A2
BR112012005338A2 BR112012005338A BR112012005338A BR112012005338A2 BR 112012005338 A2 BR112012005338 A2 BR 112012005338A2 BR 112012005338 A BR112012005338 A BR 112012005338A BR 112012005338 A BR112012005338 A BR 112012005338A BR 112012005338 A2 BR112012005338 A2 BR 112012005338A2
Authority
BR
Brazil
Prior art keywords
human
high affinity
activated receptor
protease
human antibodies
Prior art date
Application number
BR112012005338A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew J Murphy
Lynn Macdonald
Marc R Morra
Michael L Laccroix-Fralish
Nicholas J Papadopulos
Robert R Salzler
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112012005338A2 publication Critical patent/BR112012005338A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012005338A 2009-09-09 2010-09-08 anticorpos humanos de afinidade alta para receptor-2 ativado por protease humana. BR112012005338A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US24282109P 2009-09-16 2009-09-16
US31783910P 2010-03-26 2010-03-26
PCT/US2010/048034 WO2011031695A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Publications (1)

Publication Number Publication Date
BR112012005338A2 true BR112012005338A2 (pt) 2016-11-22

Family

ID=43063654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005338A BR112012005338A2 (pt) 2009-09-09 2010-09-08 anticorpos humanos de afinidade alta para receptor-2 ativado por protease humana.

Country Status (29)

Country Link
US (3) US8101724B2 (https=)
EP (1) EP2475684B1 (https=)
JP (2) JP5832435B2 (https=)
KR (1) KR101766701B1 (https=)
CN (1) CN102574923B (https=)
AR (1) AR078346A1 (https=)
AU (1) AU2010292342C1 (https=)
BR (1) BR112012005338A2 (https=)
CA (1) CA2773541A1 (https=)
CY (1) CY1118714T1 (https=)
DK (1) DK2475684T3 (https=)
ES (1) ES2609780T3 (https=)
HR (1) HRP20170324T1 (https=)
HU (1) HUE031725T2 (https=)
IL (1) IL218501A (https=)
JO (1) JO3246B1 (https=)
LT (1) LT2475684T (https=)
MX (1) MX2012002927A (https=)
MY (1) MY159551A (https=)
NZ (1) NZ599204A (https=)
PL (1) PL2475684T3 (https=)
PT (1) PT2475684T (https=)
SG (1) SG178976A1 (https=)
SI (1) SI2475684T1 (https=)
SM (2) SMT201700102T1 (https=)
TW (1) TWI492757B (https=)
UY (1) UY32883A (https=)
WO (1) WO2011031695A1 (https=)
ZA (1) ZA201201730B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
EP3778630A1 (en) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
WO2017083618A1 (en) * 2015-11-13 2017-05-18 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
JP2019534044A (ja) 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション 抗ｐｄ１および抗ｃｔｌａ４抗体
MX2019010802A (es) * 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
BR112021013824A2 (pt) * 2019-01-18 2021-12-14 Janssen Biotech Inc Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CA3136281C (en) * 2019-05-30 2024-06-25 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
CN114599351A (zh) * 2019-11-01 2022-06-07 株式会社资生堂 以皮肤中的活性型par-2为指标的皮肤状态评价方法、par-2激活促进剂或抑制剂的筛选方法和par-2激活抑制剂
CN113248611B (zh) * 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
CA3173205A1 (en) * 2020-03-31 2021-10-07 Roland B. WALTER Human anti-cd33 antibodies and uses thereof
SMT202500106T1 (it) 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso
AU2022340645A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Anti-cd33 antibodies and uses thereof
AU2022340644A1 (en) * 2021-09-02 2024-02-29 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting cd33 and uses thereof
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema
CN118290572B (zh) * 2023-09-19 2026-04-07 军事科学院军事医学研究院军事兽医研究所 抗狂犬病病毒全人源抗体及其组合物与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716789A (en) 1993-07-26 1998-02-10 Cor Therapeutics, Inc. Method to determine ligands, agonist and antagonist of C140 receptor
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
KR101360708B1 (ko) 2009-06-18 2014-02-07 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 화장료 조성물
JP2012530699A (ja) 2009-06-18 2012-12-06 株式会社アモーレパシフィック 栗皮抽出物を含む健康食品又は薬学組成物
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
CA2773541A1 (en) 2011-03-17
PL2475684T3 (pl) 2017-04-28
US8101724B2 (en) 2012-01-24
SMT201700102B (it) 2017-03-08
CY1118714T1 (el) 2017-07-12
HRP20170324T1 (hr) 2017-04-21
EP2475684B1 (en) 2016-11-30
UY32883A (es) 2011-03-31
HK1166509A1 (en) 2012-11-02
US20110059095A1 (en) 2011-03-10
KR20120059611A (ko) 2012-06-08
WO2011031695A1 (en) 2011-03-17
AU2010292342C1 (en) 2015-08-27
JP6055055B2 (ja) 2016-12-27
MX2012002927A (es) 2012-08-03
AU2010292342B2 (en) 2015-04-30
JP5832435B2 (ja) 2015-12-16
US20120093824A1 (en) 2012-04-19
ES2609780T3 (es) 2017-04-24
JP2013504577A (ja) 2013-02-07
KR101766701B1 (ko) 2017-08-09
NZ599204A (en) 2014-05-30
AU2010292342A1 (en) 2012-05-03
US9028819B2 (en) 2015-05-12
EP2475684A1 (en) 2012-07-18
TW201121565A (en) 2011-07-01
AR078346A1 (es) 2011-11-02
JP2015227381A (ja) 2015-12-17
DK2475684T3 (en) 2017-03-06
SG178976A1 (en) 2012-04-27
IL218501A (en) 2017-03-30
IL218501A0 (en) 2012-07-31
US20140179903A1 (en) 2014-06-26
HUE031725T2 (en) 2017-08-28
TWI492757B (zh) 2015-07-21
US8425907B2 (en) 2013-04-23
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
CN102574923B (zh) 2016-12-07
LT2475684T (lt) 2017-01-25
JO3246B1 (ar) 2018-03-08
PT2475684T (pt) 2017-02-10
ZA201201730B (en) 2012-11-28
SI2475684T1 (sl) 2017-03-31
CN102574923A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
BR112012005338A2 (pt) anticorpos humanos de afinidade alta para receptor-2 ativado por protease humana.
HRP20170138T1 (hr) Ponovno dobivanje proteina
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
LTC2356151I2 (lt) Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius
BRPI1011005A2 (pt) anticorpos anti-epcam
BRPI1006519A2 (pt) formulação de anticorpos
PT3195880T (pt) Formulações de anticorpos antiesclerostina de concentração elevada
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
HUE038908T2 (hu) 191P4D12 proteinekhez kötõdõ antitest-gyógyszerkonjugátumok (ADC)
EP2473531A4 (en) Anti-gitr antibodies
BRPI0918947A2 (pt) proteína de fusão de anticorpo
PT2406284T (pt) Anticorpos anti-bcma
HRP20181320T1 (hr) Ljudska anti-tau protutijela
CO6801637A2 (es) Formulaciones de anticuerpos
BR112014028600A2 (pt) formulações de anticorpo monoclonal de alta concentração
BR112013006403A2 (pt) purificação de anticorpos usando cromatografia de leito móvel simulado
BR112015003838A2 (pt) formulações de anticorpo e proteína
PT2406399T (pt) Proteínas mirac
EP2714084A4 (en) FC RECEPTOR BINDING PROTEINS
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
DK2932980T3 (da) Multivalent pneumokok-polysaccharid-proteinkonjugatsammensætning
EP2545080A4 (en) NPP1 FUSION PROTEIN
SMT201500203B (it) Proteina di fusione anticancro
EP2406388A4 (en) OX40 / TRAIL-FUSION PROTEIN
DOP2011000347A (es) Proteina de enlace de il-13

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2530 DE 02-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.